Alzheimer's drugs may help patients with glaucoma

Article

Drugs which slow the progress of Alzheimer's disease may also protect patients at risk of eye damage from glaucoma.

Drugs which slow the progress of Alzheimer's disease may also protect patients at risk of eye damage from glaucoma, according to researchers at the University College London (UCL), UK.

By examining nerve cell damage in the retina, the researchers discovered that the protein beta-amyloid, which causes damaging plaques in the brains of Alzheimer's patients, is also responsible for harm to the optic nerve. Drugs that reverse the build-up of beta-amyloid plaques were then used on rats and it was found that they reduced the rate of nerve cell death in the eye.

The UCL team, led by Francesca Cordeiro, stressed that despite the strong similarities between the two conditions, people with glaucoma are not at higher risk of developing Alzheimer's and vice versa.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.